Argenica (ASX:AGN) show ARG-007 to inhibit a key Alzheimer’s protein

Argenica (ASX:AGN) show ARG-007 to inhibit a key Alzheimer’s protein

November 3, 2023 Off By Tom Duggan

Argenica Therapeutics has received preclinical data from two separate studies showing that its novel therapeutic significantly inhibits the cellular uptake and aggregation of the tau protein in two different in vitro Alzheimer’s disease models, confirming an impact on a number of key proteins related to neurodegenerative diseases.

The studies established ARG-007’s capacity to significantly reduce the uptake of abnormal tau into brain cells with a 68 and 49 per cent reduction and also confirmed an inhibition of intracellular aggregation by up to 89 and 35 per cent.

It shows a potential mechanism to limit the spread of a protein thought to be a leading cause of Alzheimer’s progression, and alongside restriction of other key proteins, further raises the profile of ARG-007 as an exciting multimodal protein targeting therapeutic.

Argenica Managing Director Dr Liz Dallimore said the development was extremely encouraging.

“It provides further confirmation that ARG-007 can act on multiple targets and in multiple ways, making it an ideal drug candidate for neurodegenerative conditions such as Alzheimer’s disease. We look forward to continuing to progress this exciting opportunity into further animal studies,” Dr Dallimore said.

There is yet to be an approved drug targeting tau protein aggregation and cellular uptake, and with an ageing population, the World Health Organization predict the economic cost burden of Alzheimer’s will range as high as US$2.8 trillion by 2030.

And ARG-007 has shown effectiveness on a wide range of neurodegenerative diseases after being first conceived as a treatment to reduce brain tissue death after stroke.

It has since been shown to reduce the cellular uptake of alpha-synuclein, the ‘Parkinson’s Protein’, aggregates by 84 per cent, with the inhibitory effect increasing up to 90 per cent with further doses, and also to significantly reduce braincell damage caused by traumatic brain injuries.

Argenica has also received a grant to fund the pre-clinical efficacy studies required to initiate a clinical trial in newborn infants suffering from hypoxic-ischaemic encephalopathy – something which could lead to a medical breakthrough given there is still no therapeutic drug of its kind on the market.

[mstock id=”7428″]

Please note the following valuable information before using this website. 

Independent Research 

Market Open Australia is intended to be used only for educational and informative purposes, and any information on this website should not be taken as investment advice or guidance. It is important to conduct your own research before making any investment decisions, which should be based on your own investment needs and personal circumstances. Any investment decisions based on information contained on this website should be taken in line with independent financial advice from a qualified professional or should be independently researched and verified. 

We are a boutique environment – the home of uncompromisingly high-quality brands spanning news, opinion, and interaction, priding ourselves on promoting discussion and understanding that facilitates growth. We work closely with our clients to really understand what they are trying to achieve and use best practice available to do that!

Contact info

Suite 3, 47 Havelock Street
West Perth WA 6005
info@marketopen.com.au

Stewart Walters
Managing Director
stewart@marketopen.com.au
+61 414 644 166

Amanda Ellis
Chief Content Producer
amanda@marketopen.com.au
+61 438 003 868

Important links

Follow us